Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H12N4O.ClH |
Molecular Weight | 216.668 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCC1=NOC(=N1)C2CNC=NC2
InChI
InChIKey=FVWAMONNJGNNHY-UHFFFAOYSA-N
InChI=1S/C8H12N4O.ClH/c1-2-7-11-8(13-12-7)6-3-9-5-10-4-6;/h5-6H,2-4H2,1H3,(H,9,10);1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C8H12N4O |
Molecular Weight | 180.2071 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
MCD-386CR (CDD-0102A) is a functionally selective agonist with partial agonist activity at M1 muscarinic receptors, weak activity at M3 receptors, and no activity at other muscarinic receptor subtypes. In preclinical studies, it enhances memory function in animal models of Alzheimer's disease. MCD-386CR (CDD-0102A) received orphan drug designation from FDA in 2011. The drug is intended to treat progressive supranuclear palsy, a degenerative brain disease that affects balance, walking, speech, cognition, and eye movements.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. | 1993 Apr 2 |
|
Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors. | 2000 Mar |
|
The utility of muscarinic agonists in the treatment of Alzheimer's disease. | 2002 Aug-Oct |
|
The selective M1 muscarinic cholinergic agonist CDD-0102A enhances working memory and cognitive flexibility. | 2012 Mar |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 21:17:41 GMT 2023
by
admin
on
Fri Dec 15 21:17:41 GMT 2023
|
Record UNII |
6P87MRR8OA
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
327510
Created by
admin on Fri Dec 15 21:17:41 GMT 2023 , Edited by admin on Fri Dec 15 21:17:41 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6P87MRR8OA
Created by
admin on Fri Dec 15 21:17:41 GMT 2023 , Edited by admin on Fri Dec 15 21:17:41 GMT 2023
|
PRIMARY | |||
|
44472513
Created by
admin on Fri Dec 15 21:17:41 GMT 2023 , Edited by admin on Fri Dec 15 21:17:41 GMT 2023
|
PRIMARY | |||
|
1196130-86-5
Created by
admin on Fri Dec 15 21:17:41 GMT 2023 , Edited by admin on Fri Dec 15 21:17:41 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |